Clinical trials: Recurrent Epithelial Ovarian Cancer
Cancer, Ovarian Cancer
A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
This was an open-label, single-arm, Phase II study in which amcasertib (BBI503) was administered to adult, asymptomatic patients with recurrent ovarian cancer who had elevated CA-125.
- Trial name
- NCT02432690
- Testing
- BBI503
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sumitomo Pharma America, Inc.
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.
According to the definition of National Comprehensive Cancer Network (NCCN), ovarian clear cell carcinoma (OCCC) is a less common subtype of epithelial ovarian cancer (EOC) .
- Trial name
- CC-ANNIE (NCT05130515)
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Cancer
Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00002474
- Testing
- carboplatin, cyclophosphamide, mitoxantrone hydrochloride
- Where
- United States
- Sponsor
- Loyola University
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies the side effects and how well sunitinib malate works in treating patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer
- Trial name
- NCT00388037
- Testing
- sunitinib malate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer
This study plans to enroll 80 patients with locally advanced cervical cancer (stage IB-ⅣA) confirmed by histology or cytology (according to the 2018 FIGO staging standard), who are expected to receive surgical resection or…
- Trial name
- NCT06283875
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Ovarian Neoplasms
Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer
Ovarian cancer may be caused by a build-up of genetic defects, or damaged genes within the body's cells. When genes are damaged, the body may be unable to produce a group of proteins, called cytokines, used by the immune system…
- Trial name
- NCT00473954
- Testing
- EGEN-001 (phIL-12-005/PPC)
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- EGEN, Inc.
Ovarian Cancer
Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma
Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate.
- Trial name
- EPOCA (NCT07540403)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ovarian Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003080
- Testing
- endocrine-modulating drug therapy, melphalan, mitoxantrone hydrochloride
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Cancer
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
The goal of this phase II single arm prospective clinical study is to evaluate the efficacy and toxicity of pamiparib + tamoxifen regimen in epithelial ovarian cancer patients with biochemical recurrence during first-line PARPi…
- Trial name
- NCT05669768
- Testing
- Pamiparib/Tamoxifen
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Fallopian Tube Cancer, Ovarian Cancer
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003160
- Testing
- paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Theradex
Recurrent Ovarian Cancer
To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer.
- Trial name
- NCT07651124
- Testing
- autologous tumor-infiltrating lymphocytes
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Yong Wha Moon
Fallopian Tube Cancer, Ovarian Cancer
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
purpose Primary endpoint To evaluate the 24 month disease free survival Second endpoints To evaluate the 24 month overall survival To analyze the toxicity and the quality of life
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01570582
- Testing
- carboplatin and paclitaxel
- Where
- South Korea
- Volunteers
- 314 people
- Sponsor
- Korean Gynecologic Oncology Group
Anxiety Disorder, Depression
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
This pilot clinical trial studies stress reduction in improving quality of life in patients with recurrent gynecologic or breast cancer.
- Conditions
- Anxiety Disorder, Depression, Fatigue, Leydig Cell Tumor
- Trial name
- NCT01764789
- Testing
- questionnaire administration, quality-of-life assessment, psychosocial assessment and care
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Endometrial Cancer, Kidney Cancer
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving chemotherapy after surgery is more effective than surgery alone in…
- Conditions
- Endometrial Cancer, Kidney Cancer, Ovarian Cancer, Pheochromocytoma
- Trial name
- NCT00002641
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 45 sites in Austria, Belgium and 11 more
- Volunteers
- 350 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer
Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer
The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment…
- Trial name
- K19017-004 (NCT05684731)
- Testing
- KM1, Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
D010051, Ovarian Cancer
Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery
This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indicators (QIs) in advanced ovarian cancer surgery.
- Conditions
- D010051, Ovarian Cancer, Advanced-stage Ovarian Cancer, FIGO Stages III and IV
- Trial name
- retroESGO ov1 (NCT07567573)
- Testing
- Preoperative Evaluations, Cytoreductive Surgery, Perioperative Management
- Where
- Belgium
- Volunteers
- 11,383 people
- Sponsor
- European Society of Gynaecological Oncology
Primary Peritoneal Cancer, Fallopian Tube Cancer
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RC88 monotherapy in subjects with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer.
- Conditions
- Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT06173037
- Testing
- RC88
- Where
- 30 sites in China
- Volunteers
- 43 people
- Sponsor
- RemeGen Co., Ltd.
Tumor Recurrence, Malignant Epithelial Neoplasm of Vulva
Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies
The study aims to obtain a local control rate in patients with lateral pelvic relapses of gynecologycal cancers previously irradiated.
- Conditions
- Tumor Recurrence, Malignant Epithelial Neoplasm of Vulva, Malignant Epithelial Tumor of Ovary, Malignant Epithelial Neoplasm
- Trial name
- CYCLOPS (NCT05457595)
- Testing
- carbon ion radiation therapy
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05112601
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 138 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00768144
- Testing
- Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.